Letter on “(1,3)-β-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial”

Documenti analoghi

• (1,3)-β-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial
  di: De Pascale, Gennaro, et al.
  Pubblicazione: (2020)
• Impact of the Beta-Glucan Test on Management of Intensive Care Unit Patients at Risk for Invasive Candidiasis
  di: Kritikos, Antonios, et al.
  Pubblicazione: (2020)
• Galactomannan and 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Aspergillosis
  di: Lamoth, Frédéric
  Pubblicazione: (2016)
• Correlation of Clinical Outcomes with β-Glucan Levels in Patients with Invasive Candidiasis
  di: Sims, Charles R., et al.
  Pubblicazione: (2012)
• Utility of Serial β-d-Glucan Levels in Patients with High Risk for Invasive Candidiasis: A Potential Tool for Antifungal Stewardship
  di: Chua, Alvin Qijia, et al.
  Pubblicazione: (2017)